Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases

General Hospital Psychiatry

Volumn 33, Issue 1, 2011, Pages 83.e1-83.e3

  Schellekens, Arnt F A ^a   Mulder, Sasja F ^a   van Eijndhoven, Philip F P ^a   Smilde, Tineke J ^b   van Herpen, Carla M L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

Advanced renal cell cancer; Psychotic symptoms; Sunitinib treatment

Indexed keywords

ALPHA INTERFERON; HALOPERIDOL; RISPERIDONE; SUNITINIB;

ADULT; ADVANCED CANCER; ARTICLE; AUDITORY HALLUCINATION; BRAIN ISCHEMIA; CASE REPORT; CEREBELLUM; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; METASTASIS POTENTIAL; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAAORTIC LYMPH NODE; PARANOIA; PARIETAL CORTEX; PSYCHOSIS; SLEEP DISORDER; VISUAL HALLUCINATION;

EID: 79951851752     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2010.09.008     Document Type: Article

References (23)

1. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-124.
2. Motzer R.J., Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006, 24(35):5601-5608.
3. Stein M.N., Flaherty K.T. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007, 13(13):3765-3770.
4. Wong E., Rosen L.S., Mulay M., Vanvugt A., Dinolfo M., Tomoda C., et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007, 17(4):351-355.
5. Gillessen S., Graf L., Korte W., Cerny T. Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Engl J Med 2007, 356(22):2330-2331.
6. Faivre S., Raymond E., Boucher E., Douillard J., Lim H.Y., Kim J.S., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009, 10(8):794-800.
7. Gore M.E., Szczylik C., Porta C., Bracarda S., Bjarnason G.A., Oudard S., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10(8):757-763.
8. Martin G., Bellido L., Cruz J.J. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007, 25(23):3559.
9. van der Veldt A.A., van den Eertwegh A.J., Hoekman K., Barkhof F., Boven E. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol 2007, 18(10):1747-1750.
10. Kollmannsberger C., Soulieres D., Wong R., Scalera A., Gaspo R., Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007, 1(2 Suppl):S41-S54.
11. Katoh M., Nakajima M., Shimada N., Yamazaki H., Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000, 55(11-12):843-852.
12. Nishio S., Watanabe H., Kosuge K., Uchida S., Hayashi H., Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005, 28(3):223-227.
13. Patyna S., Peng G. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer Suppl 2006, 4(12):21.
14. Hill K.L., Lipson A.C., Sheehan J.M. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. J Neurosurg 2009, 111(3):497-503.
15. Blumberg H.P., Wang F., Chepenik L.G., Kalmar J.H., Edmiston E., Duman R.S., et al. Influence of vascular endothelial growth factor variation on human hippocampus morphology. Biol Psychiatry 2008, 64(10):901-903.
16. Rosenstein J.M., Krum J.M. New roles for VEGF in nervous tissue-beyond blood vessels. Exp.Neurol. 2004, 187(2):246-253.
17. Parikh AA, Ellis LM. The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am. 18(5):2004;951--71, vii.
18. Huang Y.F., Yang C.H., Huang C.C., Tai M.H., Hsu K.S. Pharmacological and genetic accumulation of hypoxia-inducible factor-1alpha enhances excitatory synaptic transmission in hippocampal neurons through the production of vascular endothelial growth factor. J.Neurosci 2010, 30(17):6080-6093.
19. McCloskey D.P., Croll S.D., Scharfman H.E. Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. J Neurosci 2005, 25(39):8889-8897.
20. Buckley P.F., Mahadik S., Pillai A., Terry A. Neurotrophins and schizophrenia. Schizophr Res 2007, 94(1-3):1-11.
21. Keilhoff G., Grecksch G., Bernstein H.G., Roskoden T., Becker A. Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. Eur Arch Psychiatry Clin Neurosci 2010, 260(2):151-162.
22. Fulzele S., Pillai A. Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects. Schizophr Res 2009, 115(2-3):372-373.
23. Pillai A., Mahadik S.P. Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus. Schizophr Res 2006, 87(1-3):48-59.